Zejing Pharmaceutical (688266.SH) issued an announcement. The company recently received from the State Drug Administration (hereinafter referred to as...
Zhitong Finance App News, Zejing Pharmaceutical (688266.SH) issued an announcement. The company recently received the “Drug Clinical Trial Approval Notice” approved and issued by the China Drug Administration (hereinafter referred to as the “State Drug Administration”). The phase II/III clinical trial of jacktinib hydrochloride cream for the treatment of adolescents and adults with non-segmental vitiligo aged 12 and above was approved.
Allegedly, jacketinib hydrochloride is a novel JAK inhibitor drug independently developed by the company. It is a Class 1 new drug, and the company has independent intellectual property rights for this product. Jacktinib has significant inhibitory effects on Janus kinases including JAK1, JAK2, JAK3, and TYK2, and has the strongest inhibitory effect on JAK2 and TYK2. The possible mechanism of action of jacktinib is to block the JAK-STAT signaling pathway, directly or indirectly block signal transduction of various related cytokines, and inhibit excessive or abnormal immunity.